11 results on '"Mahajan, Vinit B."'
Search Results
2. Fundoscopy-directed genetic testing to re-evaluate negative whole exome sequencing results
- Author
-
Cho, Ahra, Lima de Carvalho, Jr, Jose Ronaldo, Tanaka, Akemi J., Jauregui, Ruben, Levi, Sarah R., Bassuk, Alexander G., Mahajan, Vinit B., and Tsang, Stephen H.
- Published
- 2020
- Full Text
- View/download PDF
3. Chorioretinal atrophy following voretigene neparvovec despite the presence of fundus autofluorescence.
- Author
-
Kolesnikova, Masha, Lima de Carvalho, Jose Ronaldo, Parmann, Rait, Kim, Angela H., Mahajan, Vinit B., Tsang, Stephen H., and Sparrow, Janet R.
- Subjects
BIOFLUORESCENCE ,ATROPHY ,GENE therapy ,BLINDNESS - Abstract
Introduction: Leber congenital amaurosis (LCA) type 2, due to disease‐causing variants in RPE65, is characterized by severe visual loss in early infancy. Current treatments include voretigene neparvovec‐rzyl (VN) for RPE65‐associated LCA. Herein, we present the long‐term follow‐up of a patient treated with VN using quantitative autofluorescence (488 nm excitation). Case Report: A 9‐year‐old girl with a diagnosis of LCA with biallelic variants in RPE65 presented for evaluation. The patient underwent VN treatment at the age of 11. The patient returned to clinic at age of 19 at which time imaging revealed evidence of chorioretinal atrophy. Quantitative autofluorescence performed prior to gene therapy and at 6‐ and 8‐year follow‐up revealed a central area of fundus autofluorescence. Discussion This case report demonstrates acquisition of fundus autofluorescence at 6‐ and 8‐year follow‐up despite the development of chorioretinal atrophy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Genome Surgery and Gene Therapy in Retinal Disorders
- Author
-
Chan, Lawrence, Mahajan, Vinit B., and Tsang, Stephen H.
- Subjects
Gene Editing ,Clinical Trials as Topic ,iPSC ,clinical trials ,genome surgery ,Leber Congenital Amaurosis ,Review ,Genetic Therapy ,gene therapy ,ophthalmology ,Macular Degeneration ,Retinal Diseases ,CRISPR ,inherited retinal disease ,Humans ,CRISPR-Cas Systems ,Retinitis Pigmentosa - Abstract
The emergence of genome surgery techniques like the clustered regularly interspaced short palindromic repeats (CRISPR) editing technology has given researchers a powerful tool for precisely introducing targeted changes within the genome. New modifications to the CRISPR-Cas system have been made since its recent discovery, such as high-fidelity Cas9 variants to reduce off-target effects and transcriptional activation/silencing with CRISPRa/CRISPRi. The applications of CRISPR-Cas and gene therapy in ophthalmic diseases have been necessary and fruitful, especially given the impact of blinding diseases on society and the large number of monogenic disorders of the eye. This review discusses the impact that CRISPR-Cas has had on furthering our understanding of disease mechanisms and potential therapies for inherited eye diseases. Furthermore, we explore a brief overview of recent and ongoing gene therapy clinical trials in retinal diseases, and conclude with the implications of genome surgery on the outlook of future therapeutic interventions.
- Published
- 2017
5. Investigation of Cas9 antibodies in the human eye.
- Author
-
Toral, Marcus A., Charlesworth, Carsten T., Ng, Benjamin, Chemudupati, Teja, Homma, Shota, Nakauchi, Hiromitsu, Bassuk, Alexander G., Porteus, Matthew H., and Mahajan, Vinit B.
- Subjects
IMMUNOGLOBULINS ,EYE inflammation ,BACTERIAL diseases ,VISION disorders ,GENE therapy ,CRISPRS - Abstract
Preexisting immunity against Cas9 proteins in humans represents a safety risk for CRISPR–Cas9 technologies. However, it is unclear to what extent preexisting Cas9 immunity is relevant to the eye as it is targeted for early in vivo CRISPR–Cas9 clinical trials. While the eye lacks T-cells, it contains antibodies, cytokines, and resident immune cells. Although precise mechanisms are unclear, intraocular inflammation remains a major cause of vision loss. Here, we used immunoglobulin isotyping and ELISA platforms to profile antibodies in serum and vitreous fluid biopsies from human adult subjects and Cas9-immunized mice. We observed high prevalence of preexisting Cas9-reactive antibodies in serum but not in the eye. However, we detected intraocular antibodies reactive to S. pyogenes-derived Cas9 after S. pyogenes intraocular infection. Our data suggest that serum antibody concentration may determine whether specific intraocular antibodies develop, but preexisting immunity to Cas9 may represent a lower risk in human eyes than systemically. Pre-existing antibodies against Cas9 proteins represent a potential issue for gene therapies, including those targeting the eye. Here the authors assess the presence of intraocular antibodies, and show that Cas9 antibodies were prevalent in human serum but not the eye, unless prior bacterial infection occurred. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. CAPN5 genetic inactivation phenotype supports therapeutic inhibition trials.
- Author
-
Wert, Katherine J., Koch, Susanne F., Velez, Gabriel, Hsu, Chun‐Wei, Mahajan, MaryAnn, Bassuk, Alexander G., Tsang, Stephen H., and Mahajan, Vinit B.
- Abstract
Small molecule pharmacological inhibition of dominant human genetic disease is a feasible treatment that does not rely on the development of individual, patient‐specific gene therapy vectors. However, the consequences of protein inhibition as a clinical therapeutic are not well‐studied. In advance of human therapeutic trials for CAPN5 vitreoretinopathy, genetic inactivation can be used to infer the effect of protein inhibition in vivo. We created a photoreceptor‐specific knockout (KO) mouse for Capn5 and compared the retinal phenotype to both wild‐type and an existing Capn5 KO mouse model. In humans, CAPN5 loss‐of‐function (LOF) gene variants were ascertained in large exome databases from 60,706 unrelated subjects without severe disease phenotypes. Ocular examination of the retina of Capn5 KO mice by histology and electroretinography showed no significant abnormalities. In humans, there were 22 LOF CAPN5 variants located throughout the gene and in all major protein domains. Structural modeling of coding variants showed these LOF variants were nearby known disease‐causing variants within the proteolytic core and in regions of high homology between human CAPN5 and 150 homologs, yet the LOF of CAPN5 was tolerated as opposed to gain‐of‐function disease‐causing variants. These results indicate that localized inhibition of CAPN5 is a viable strategy for hyperactivating disease alleles. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
7. Gene therapy and genome surgery in the retina.
- Author
-
DiCarlo, James E., Mahajan, Vinit B., and Tsang, Stephen H.
- Subjects
- *
RETINAL surgery , *INDIVIDUALIZED medicine , *GENE therapy , *IMMUNOSPECIFICITY , *DISEASE progression , *GENETIC engineering - Abstract
Precision medicine seeks to treat disease with molecular specificity. Advances in genome sequence analysis, gene delivery, and genome surgery have allowed clinician-scientists to treat genetic conditions at the level of their pathology. As a result, progress in treating retinal disease using genetic tools has advanced tremendously over the past several decades. Breakthroughs in gene delivery vectors, both viral and nonviral, have allowed the delivery of genetic payloads in preclinical models of retinal disorders and have paved the way for numerous successful clinical trials. Moreover, the adaptation of CRISPR-Cas systems for genome engineering have enabled the correction of both recessive and dominant pathogenic alleles, expanding the disease-modifying power of gene therapies. Here, we highlight the translational progress of gene therapy and genome editing of several retinal disorders, including RPE65-, CEP290-, and GUY2D-associated Leber congenital amaurosis, as well as choroideremia, achromatopsia, Mer tyrosine kinase- (MERTK-) and RPGR X-linked retinitis pigmentosa, Usher syndrome, neovascular age-related macular degeneration, X-linked retinoschisis, Stargardt disease, and Leber hereditary optic neuropathy. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
8. CAPN5 gene silencing by short hairpin RNA interference.
- Author
-
Nelson, Nnamdi G., Skeie, Jessica M., Muradov, Hakim, Rowell, Hannah A., Seongjin Seo, and Mahajan, Vinit B.
- Subjects
RNA ,POLYCYSTIC kidney disease ,ALLELES ,PLASMIDS ,GENE silencing - Abstract
Background: The purpose of this project was to identify short hairpin RNA (shRNA) sequences that can suppress expression of human CAPN5 in which gain-of-function mutants cause autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV). We created HEK293T cells that stably express an ADNIV disease allele, CAPN5-p.R243L. Transfection protocols were optimized for neuroblastoma SHSY5Y cells. The gene silencing effect of four different shRNA plasmids that target CAPN5 was tested. RNA and protein expression was determined using quantitative RT-PCR and immunoblot analysis. Findings: Two of four shRNA plasmids reduced mutant CAPN5 RNA in a stable cell line. Similar knockdown was observed in SH-SY5Y cells that natively express CAPN5. Lactose dehydrogenase assays showed that down-regulation of CAPN5 was not cytotoxic. Conclusions: CAPN5 expression can be suppressed by shRNA-based RNA interference. Further testing in ADNIV models will determine the potential of gene silencing as a strategy to treat, delay, or prevent blindness in ADNIV patients. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. Viral Delivery Systems for CRISPR.
- Author
-
Xu, Christine L., Ruan, Merry Z. C., Mahajan, Vinit B., and Tsang, Stephen H.
- Subjects
CRISPRS ,CELL analysis ,GENOME editing ,GENE therapy ,DNA analysis - Abstract
The frontiers of precision medicine have been revolutionized by the development of Clustered Regularly-Interspaced Short Palindromic Repeats (CRISPR)/Cas9 as an editing tool. CRISPR/Cas9 has been used to develop animal models, understand disease mechanisms, and validate treatment targets. In addition, it is regarded as an effective tool for genome surgery when combined with viral delivery vectors. In this article, we will explore the various viral mechanisms for delivering CRISPR/Cas9 into tissues and cells, as well as the benefits and drawbacks of each method. We will also review the history and recent development of CRISPR and viral vectors and discuss their applications as a powerful tool in furthering our exploration of disease mechanisms and therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. Unleashing the potential of CRISPR multiplexing: Harnessing Cas12 and Cas13 for precise gene modulation in eye diseases.
- Author
-
Bigini, Fabio, Lee, Soo Hyeon, Sun, Young Joo, Sun, Yang, and Mahajan, Vinit B.
- Subjects
- *
CRISPRS , *GENE therapy , *EYE diseases , *GENOME editing , *GENETIC disorder treatment - Abstract
• Targeting multiple genes simultaneously exhibits great potential in CRISPR therapy. • Cas9 has limitations for precise editing of multiple genes. • Cas12 and Cas13 are promising alternative enzymes for multiplexed CRISPR. • Cas13 targets RNA instead of DNA, enabling temporary yet safe gene control. • Multiplex gene editing approaches for ocular disorder treatments are proposed. Gene therapy is a flourishing field with the potential to revolutionize the treatment of genetic diseases. The emergence of CRISPR-Cas9 has significantly advanced targeted and efficient genome editing. Although CRISPR-Cas9 has demonstrated promising potential applications in various genetic disorders, it faces limitations in simultaneously targeting multiple genes. Novel CRISPR systems, such as Cas12 and Cas13, have been developed to overcome these challenges, enabling multiplexing and providing unique advantages. Cas13, in particular, targets mRNA instead of genomic DNA, permitting precise gene expression control and mitigating off-target effects. This review investigates the potential of Cas12 and Cas13 in ocular gene therapy applications, such as suppression of inflammation and cell death. In addition, the capabilities of Cas12 and Cas13 are explored in addressing potential targets related with disease mechanisms such as aberrant isoforms, mitochondrial genes, cis -regulatory sequences, modifier genes, and long non-coding RNAs. Anatomical accessibility and relative immune privilege of the eye provide an ideal organ system for evaluating these novel techniques' efficacy and safety. By targeting multiple genes concurrently, CRISPR-Cas12 and Cas13 systems hold promise for treating a range of ocular disorders, including glaucoma, retinal dystrophies, and age-related macular degeneration. Nonetheless, additional refinement is required to ascertain the safety and efficacy of these approaches in ocular disease treatments. Thus, the development of Cas12 and Cas13 systems marks a significant advancement in gene therapy, offering the potential to devise effective treatments for ocular disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Reprogramming metabolism by targeting sirtuin 6 attenuates retinal degeneration.
- Author
-
Lijuan Zhang, Jianhai Du, Justus, Sally, Chun-Wei Hsu, Bonet-Ponce, Luis, Wen-Hsuan Wu, Yi-Ting Tsai, Wei-Pu Wu, Yading Jia, Duong, Jimmy K., Mahajan, Vinit B., Chyuan-Sheng Lin, Shuang Wang, Hurley, James B., Tsang, Stephen H., Zhang, Lijuan, Du, Jianhai, Hsu, Chun-Wei, Wu, Wen-Hsuan, and Tsai, Yi-Ting
- Subjects
- *
RETINITIS pigmentosa , *RETINAL degeneration , *PHOTORECEPTORS , *CELL death , *PHOSPHODIESTERASES , *PROTEIN metabolism , *NUCLEOTIDE metabolism , *ANIMAL experimentation , *ANIMALS , *BIOLOGICAL models , *CELL differentiation , *ENERGY metabolism , *ESTERASES , *GENE therapy , *GENETICS , *GLYCOLYSIS , *MICE , *GENETIC mutation , *NUCLEOTIDES , *PROTEINS , *RESEARCH funding , *VIRUSES , *CHEMICAL inhibitors , *THERAPEUTICS - Abstract
Retinitis pigmentosa (RP) encompasses a diverse group of Mendelian disorders leading to progressive degeneration of rods and then cones. For reasons that remain unclear, diseased RP photoreceptors begin to deteriorate, eventually leading to cell death and, consequently, loss of vision. Here, we have hypothesized that RP associated with mutations in phosphodiesterase-6 (PDE6) provokes a metabolic aberration in rod cells that promotes the pathological consequences of elevated cGMP and Ca2+, which are induced by the Pde6 mutation. Inhibition of sirtuin 6 (SIRT6), a histone deacetylase repressor of glycolytic flux, reprogrammed rods into perpetual glycolysis, thereby driving the accumulation of biosynthetic intermediates, improving outer segment (OS) length, enhancing photoreceptor survival, and preserving vision. In mouse retinae lacking Sirt6, effectors of glycolytic flux were dramatically increased, leading to upregulation of key intermediates in glycolysis, TCA cycle, and glutaminolysis. Both transgenic and AAV2/8 gene therapy-mediated ablation of Sirt6 in rods provided electrophysiological and anatomic rescue of both rod and cone photoreceptors in a preclinical model of RP. Due to the extensive network of downstream effectors of Sirt6, this study motivates further research into the role that these pathways play in retinal degeneration. Because reprogramming metabolism by enhancing glycolysis is not gene specific, this strategy may be applicable to a wide range of neurodegenerative disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.